Business Wire

AlbaCore Capital Group Closes Dislocation Fund


European credit specialist AlbaCore Capital Group (“AlbaCore”) announces the final close of AlbaCore Investment Opportunities L.P. (“AIO”). AlbaCore secured over $1bn of commitments for the dislocation strategy, both in comingled and SMA format, which started investing at the depth of the crisis in mid-March. AlbaCore’s dislocation investing generated a 55% IRR1 since launch to the end of November 2020, whilst benchmark credit indices saw low single digits with year to date returns of 1.7%2. AlbaCore has generated positive returns across all strategies to date in 2020.

AlbaCore launched the dislocation strategy to engage with the opportunity in what it viewed as a credit picker’s market. The team maintained their fundamental approach and were focused on companies that they have tracked for years. Many companies which have consistently been regarded as strong credits through the end of 2019, had yet to present a double digit total return opportunity. During the 2020 dislocation, these credits came into AlbaCore’s relevant price target range, whilst maintaining their strong fundamentals. With the deep knowledge and credit underwrite in place, the team was poised to capture the opportunity.

Bill Ammons, Founding Partner and Portfolio Manager Officer at AlbaCore Capital Group, commented:

“We were in a unique position to move quickly and yet maintain AlbaCore’s disciplined process and depth of credit analysis. The team’s persistent fundamental credit research combined with our 2019 CLO warehouse launch generated an extensive watch-list that covered a significant portion of the European universe. When the price was right, we were ready.”

The launch of a dedicated dislocation strategy can be seen to consolidate AlbaCore’s position as one of the leading European specialist credit managers. AlbaCore is proud to have extended its global investor relationships, despite the challenges of a global pandemic, and extends thanks also to existing investors who continue to be valued partners.

David Allen, Founder and Chief Investment Officer at AlbaCore Capital Group, commented:

“This year has required an agile approach to investing and a razor sharp focus on risk and relative value. At AlbaCore, we have navigated the 2020 market by activating our dislocation strategy, maintaining hands-on management of our AlbaCore Partners flagship funds and significantly increasing our investments in senior secured opportunities across our strategies. We are delighted to continue to expand our product offering for our partners in a thoughtful and opportunistic way. We look forward to continuing to deliver for our investors across the credit spectrum.”

AlbaCore’s Product Strategies:

AlbaCore Partners: Both of the flagship Partners funds, which have a hybrid strategy investing in private and public credit, actively drew capital to 85% in March 2020. The funds have invested $10.4bn3 and achieved 11%4 returns since inception with significant alpha capture of +700bpswhen compared to relative benchmarks5.

Private Credit Investing: Whilst liquid market opportunities are in focus this year, AlbaCore has continued to structure a number of large, off-market, bespoke private transactions, committing $2.4bn6 of capital alongside co-investors. With this year’s activity, AlbaCore has now offered over $3.5bn7 in co-investments since inception - a core part of the AlbaCore offering.

Liquid Credit Investing: The AlbaCore team has invested over €8.7bn8 in liquid investments across strategies since inception, delivering a 10.9%9 IRR. To capitalize on this year’s market volatility and the team’s expertise, AlbaCore saw significant activity in liquid markets across the platform. This part of the AlbaCore strategy provides greater flexibility for investors and can be maneuvered to focus on specific areas of the seniority spectrum.

CLO strategy: AlbaCore priced its maiden Collateralized Loan Obligation (“CLO”) in June 2020, achieving the tightest AAA spread for a European CLO following the pandemic at time of launch10. AlbaCore combined a negative ESG screening criteria and risk focused ESG investment considerations with its agile fundamental research approach. This outcome as a first-time issuer is a testament to the broader markets’ understanding of the quality of the team and investment process at AlbaCore.

About AlbaCore Capital Group

AlbaCore is one of the leading European credit specialist focused on public and private corporate credit markets. The senior investment team have been investing with this hybrid strategy for over a decade11. Founded in 2016, AlbaCore has invested $14.7bn12 across 275 companies for global pension funds, sovereign wealth funds, consultants, insurance companies, family offices and endowments.

AlbaCore is focused on consistently outperforming the market in the long term while protecting investor capital. The credit selection process is based on fundamental research with a focus on capital preservation, ESG factors and risk-adjusted returns.

Headquartered in London and with an office in Dublin, AlbaCore has a partnership approach with values at the center of the AlbaCore community.

1 As of 30 November 2020. Gross Internal Rate of Return (“IRR”) is calculated using fully equalized cash flows between the fund and an investor as if all current investors had been committed to the fund from inception. Rate of return calculated does not include management or performance fees, which would be reflected in a net IRR (that would be lower) actually received by investors.
2 As of 30 November 2020. 50:50 blended return of S&P Leveraged Loan Index and Barclays High Yield Index.
3 Invested capital is the sum of all 'buy' trades for the referenced AlbaCore mandates during the year of 2020 through to 30 November, and includes recycled capital.
4 Gross Internal Rate of Return (“IRR”) is calculated using fully equalized cash flows between the fund and an investor as if all current investors had been committed to the fund from inception. Rate of return calculated does not include management or performance fees, which would be reflected in a net IRR (that would be lower) actually received by investors.
5 We have used BAML Euro High Yield index, S&P Euro Lev Loans Index as benchmarks for the performance of European & relevant markets for the purpose of this analysis only. Market performance figures are sourced from Bloomberg AlbaCore does not manage its portfolio on the basis of the constituents of each of benchmarks, and therefore the analysis and comparisons made here may change materially over time.
6 Invested capital is the sum of all 'buy' trades for the referenced AlbaCore mandates, for private side investing only, during the year of 2020 through to 30 November, and includes recycled capital.
7 The co-investment opportunities represent the USD equivalent aggregate amount of investment opportunities we have offered to co-investors through AlbaCore managed vehicles or by a direct investments by the co-investor. This also reflects any potential co-investment opportunities offered, but not executed.
8 Invested capital is the sum of all 'buy' trades for AlbaCore mandates (including the AlbaCore Partners Funds, co-invest sidecar to these Funds, AIO, AlbaCore’s CLO and client SMAs), and includes recycled capital.
9 As of 30 November 2020. Gross Internal Rate of Return (“IRR”) is calculated using fully equalized cash flows between the fund and an investor as if all current investors had been committed to the fund from inception. Rate of return calculated does not include management or performance fees, which would be reflected in a net IRR (that would be lower) actually received by investors.
10 Source: Bloomberg as at 07 December 2020.
11 Including period prior to AlbaCore at the Canada Pension Plan Investment Board (“CPPIB”).
12 Invested capital is the sum of all 'buy' trades for all AlbaCore mandates since inception to 30 November 2020, and includes recycled capital and co-investment.

Contact information

For media enquiries:
Kepler Communications
Charlotte Balbirnie
+44 (0)7989 528421

Caroline Villiers
+44 (0)7808 585184

About Business Wire

Business Wire
Business Wire

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Servier announce updated overall survival results of exploratory TASCO1 phase II study of LONSURF ® + bevacizumab in a first-line setting for patients with unresectable mCRC non-eligible for intensive therapy16.1.2021 22:15:00 CETPress release

Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF® (trifluridine/tipiracil) + bevacizumab and capecitabine + bevacizumab (C-B) in a first-line setting for patients with unresectable metastatic colorectal cancer (mCRC) who are non-eligible for intensive therapy.1 The data were announced today during an oral presentation at the 2021 ASCO Gastrointestinal Cancers Symposium (ASCO-GI). Patients with mCRC who are not eligible for chemotherapy face a large unmet need, with fewer treatment options available to them and lower survival rates. Colorectal cancer (CRC) makes up 9.7% of total global cancer cases, with almost 1.4 million new cases of CRC each year.2 In Europe, CRC is the second most common cause of death due to cancer, and those with a metastatic disease have a 5-year survival rate of just 11%.3 “For patients with metastatic colorectal cancer, those non-eligible for standard combination therapy have few options left and we are conti

H.I.G. Realty Invests in Production Studios & Content Hub in Madrid15.1.2021 09:00:00 CETPress release

H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with $43 billion of equity capital under management, announced today that one of its affiliates has invested in Madrid Content City, an approximately 140,000 square meter hub with state of the art audio-visual facilities, including production studios, production & post-production technical facilities, and a university focused on media studies. H.I.G. continues to add to its sizeable portfolio of real estate assets across Europe, consisting of both equity as well as debt investments, with a particular focus on its target market of value-added small and midcap opportunities. Riccardo Dallolio, Managing Director and Head of H.I.G. Europe Realty Partners, commented: “Madrid Content City will benefit from strong secular tailwinds underpinned by the boom in content production. The state-of-the-art studios and related facilities, the exceptional multinational tenant line-up with long term leases, and its critical mas

Eurofins, the global leader in analytical testing, expands worldwide face mask testing & certification capabilities15.1.2021 07:30:00 CETPress release

Since the start of the pandemic Eurofins (Paris:ERF) has tested thousands of models of surgical and hygienic masks and provided best-in-class speed and certification for PPEs globally, enabling these critical products to get market as fast as possible. Eurofins has developed global leading testing capabilities and certification services in the North America, Europe and Asia ensuring that PPE manufacturers are able to provide the indispensable support needed in the fight against the coronavirus. As of today, Eurofins is one of the few GLP certified and ISO/IEC 17025 accredited laboratory networks to fully cover all testing requirements for surgical/medical and hygienic masks by the FDA, EU regulations and many international and country-specific directives and guidelines such as CEN, CE Marking, ISO, ASTM or OECD. Our robust portfolio for masks includes globally accepted, safety and performance testing, virucidal, bacterial filtration, particle filtration, differential pressure, biocompa

TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport ® (abobotulinumtoxinA) in five therapeutic indications15.1.2021 07:00:00 CETPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced results from new analyses of pivotal Phase III clinical trial data to assess treatment intervals over repeat cycles of Dysport® (abobotulinumtoxinA [aboBoNT-A]) in five patient populations. AbobotulinumtoxinA: Evidence for Long Duration of Response from 5 Patient Populations is being shared during the TOXINS 2021 conference, which is taking place virtually between 16-17 January 2020 and is organized by the International Neurotoxin Association.1-28 Ipsen is sharing 26 abstracts during the congress, with data including updates from the recently published surveys into the experience of patients and caregivers, data from the Phase IV ULIS-III trial, and ten abstracts focused on basic science research into neurotoxins.1-27 Spasticity is one of the most common and disabling conditions associated with many neurological conditions in adults and is characterized by velocity-dependent muscle hypertonia. Spasticity can lead to disabilit

Velodyne Lidar Commends NHTSA Plan to Update NCAP14.1.2021 21:58:00 CETPress release

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today commended the U.S. Department of Transportation’s National Highway Traffic Safety Administration (NHTSA) plan to update to its New Car Assessment Program (NCAP). The NHTSA proposal would add four advanced driver assistance system (ADAS) capabilities to the NCAP, keeping pace with evolving safety technologies and providing much-needed information to consumers. This press release features multimedia. View the full release here: Images show vehicle with lidar-based PAEB stopping before adult target @ 50% overlap (above) and vehicle with camera and radar-based PAEB crashing into adult target (below). (Photo: Velodyne Lidar, Inc.) NCAP is the U.S. Government’s premier consumer information program for evaluating vehicle safety performance. The NHTSA proposal to add ADAS technologies to the NCAP includes pedestrian automatic emergency braking, lane keeping support, blind spot warning and

Snow Software Recognized as a 2020 Gartner Peer Insights Customers’ Choice for Software Asset Management14.1.2021 20:39:00 CETPress release

Snow Software, the global leader in technology intelligence, today announced that the company was named a December 2020 Gartner Peer Insights Customers’ Choice for Software Asset Management (SAM) Tools. Gartner defines software asset management tools as technology that “automates many of the tasks required to maintain compliance with software licenses, thereby controlling software spending.” This is the fourth Gartner Peer Insights Customers’ Choice announcement for SAM, and Snow has earned the distinction all four times. Based solely on feedback from verified customers, Gartner Peer Insights Customers’ Choice reflects reviews and ratings published within the last 12 months. Snow received 100 reviews – the most of any vendor in the market – with an overall rating of 4.6 out of 5 as of January 12, 2021. Earlier this year, Snow was recognized as a Leader in Gartner’s 2020 Magic Quadrant for Software Asset Management Tools1 and received the highest scores in three out of four use cases in

Veristat Supported Marketing Applications for 10% of All FDA Novel Drug Approvals in 202014.1.2021 19:15:00 CETPress release

Veristat, a scientific-minded global clinical research organization (CRO), announced today that they supported the marketing applications for 10% of the 2020 US Food and Drug Administration (FDA) novel drug approvals. The FDA approved 53 novel drugs, defined by the FDA as New Molecular Entities (NMEs)i, and Veristat regulatory, statistical, and medical writing experts were integral in preparing five of these NME New Drug Applications. Veristat also prepared NDA/BLAs for three non-NME FDA approvals and one Marketing Authorization Application (MAA) that received approval in Europe. "Despite the global challenges in 2020, Veristat continued to advance its mission of helping clients achieve regulatory approval of novel medical therapies," stated Patrick Flanagan, Chief Executive Officer at Veristat. "Now, more than ever, Veristat is focused on providing expert guidance to facilitate the rapid approval for therapies that improve the lives of patients and their families around the world." Ve

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom